Company: INDP
Filing Date: 2025-06-23
Form Type: DEF 14A
Source: 0001641172-25-016071
Chunk: 16

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-23
Form: DEF 14A
Chunk 16
---
 Meckler in the Private Placement in accordance with the terms of the Note and Common Warrant.

If stockholders approve this proposal, the rights
or privileges of our existing stockholders will not be affected, except that the economic and voting interests of each of our existing
stockholders will be diluted. Although the number of shares of our common stock that our existing stockholders own will not decrease,
the shares of our common stock owned by our existing stockholders will represent a smaller percentage of our total outstanding shares
of our common stock after any such issuance. Because the Conversion Price of the Notes and the exercise price of the Common Warrants
are dependent upon the trading price of our common stock in the future, the exact magnitude of the dilutive effect cannot be conclusively
determined. However, the dilutive effect may be material to our current stockholders.

Vote Required

The proposal requires the affirmative vote of
the holders of a majority in voting power of the votes cast affirmatively or negatively. Abstentions will have the same legal effect
as a negative vote. Broker non-votes will have no effect on the proposal.

Recommendation of the Board of Directors

The Board of Directors unanimously recommends a vote FOR the Related Party Proposal.

<div align='center'>9

STOCKHOLDERS’ PROPOSALS</div>

Stockholders who intend to have a proposal considered
for inclusion in our proxy materials for presentation at our 2026 annual meeting of stockholders (the “2026 Annual Meeting”)
pursuant to Rule 14a-8 under the Exchange Act must submit the proposal to our Secretary at our offices at 3 Columbus Circle, 15Floor, New York, NY 10019 in writing not later than December 29, 2025.

Stockholders intending to present a proposal
at the 2026 Annual Meeting, but not to include the proposal in our proxy statement, or to nominate a person for election as a director,
must comply with the requirements set forth in our Amended and Restated Bylaws. Our Amended and Restated Bylaws require, among other
things, that our Secretary receive written notice from the stockholder of record of their intent to present such proposal or nomination
not less than 90 days nor more than 120 days prior to the one-year anniversary of the preceding year’s annual meeting. Therefore,
we must receive notice of such a proposal or nomination for the 2026 Annual Meeting no earlier than February 10, 2026 and no later than